文献速递银屑病与炎症性皮肤病

PGA×BSA复合指标与PASI在斑块状银屑病严重程度及Cal/BD泡沫治疗反应评估中的比较

PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2020-05-16

该事后分析基于3项随机对照试验,比较PGA×BSA与mPASI在评估轻、中、重度银屑病严重程度及Cal/BD泡沫治疗反应中的表现。结果显示两者在第1、2、4周达到75%反应的患者比例相似且均显著优于载体,第4周平均改善分别为51.0%和50.7%;两者相关性随疾病严重程度增加而升高。

要点

  • PGA×BSA与mPASI在评估Cal/BD泡沫疗效时表现相似。
  • 两者相关性在重度银屑病中最高,轻度最低。
  • PGA×BSA或可作为更简便的疗效评估工具。

核心结论

  • 汇总数据分析显示PGA×BSA与mPASI的相关性随银屑病严重程度增加而升高。

研究设计与样本

  • 基于3项随机对照试验(NCT01536886、NCT01866163、NCT02132936)的事后分析,评估Cal/BD泡沫在轻、中、重度银屑病中的疗效。
  • 采用Spearman相关和Bland-Altman图比较PGA×BSA与mPASI。

主要发现

  • 第1、2、4周时,Cal/BD泡沫组达到PGA×BSA和mPASI 75%反应的患者比例相似,且在所有时间点均显著高于载体组(P ≤ .002)。
  • 第4周时,PGA×BSA和mPASI的平均改善分别为51.0%和50.7%。
  • 基线时轻度、中度、重度银屑病的Spearman相关系数分别为r=.51、.72、.86(n=126、465、58),第4周分别为r=.80、.81、.89(n=121、452、58)(P < .001)。

关键数值与推荐

  • 第1、2、4周达到75%反应的比例在PGA×BSA与mPASI之间相似,且均显著优于载体(P ≤ .002)。
  • 第4周平均改善:PGA×BSA 51.0%,mPASI 50.7%。
  • 基线相关系数:轻度r=.51(n=126),中度r=.72(n=465),重度r=.86(n=58);第4周:轻度r=.80(n=121),中度r=.81(n=452),重度r=.89(n=58)(P < .001)。

临床怎么用

  • PGA×BSA使用更简便,在评估Cal/BD泡沫治疗反应时与mPASI结果相似,可考虑用于临床疗效监测。
  • 在重度银屑病患者中,PGA×BSA与mPASI相关性更高,评估一致性更好。

局限性

  • 汇总数据来自不同试验,事后分析未预先设定。
  • 未评估评估者间信度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The product of the Physician Global Assessment and body surface area (PGA×BSA) is simpler to use than the Psoriasis Area and Severity Index (PASI), which lacks sensitivity in patients with mild psoriasis. OBJECTIVE: To compare the PGA×BSA versus the modified PASI (mPASI) for assessing disease severity and therapeutic response to calcipotriol/betamethasone dipropionate (Cal/BD) foam. METHODS: This post hoc analysis evaluated the efficacy of Cal/BD foam in mild, moderate, and severe psoriasis, as assessed by the PGA×BSA and mPASI, using data from 3 randomized controlled trials (NCT01536886, NCT01866163, NCT02132936). Spearman correlation and Bland-Altman plots were used to compare the PGA×BSA with the mPASI. RESULTS: Proportions of patients receiving Cal/BD foam achieving 75% response for PGA×BSA and mPASI at weeks 1, 2, and 4 were similar and significantly greater than with vehicle (P ≤ .002 at all timepoints); at week 4, mean improvements were 51.0% and 50.7%, respectively. Spearman correlations for mild, moderate, and severe psoriasis were moderate to high between PGA×BSA and mPASI at baseline (r = .51, .72, and .86, respectively; n = 126, 465, and 58, respectively) and high at week 4 (r = .80, .81, and .89, respectively; n = 121, 452, and 58, respectively) (P < .001). LIMITATIONS: Pooled data from different trials were not prespecified for post hoc analysis. Interrater reliability was not assessed. CONCLUSION: Pooled data analysis showed that the PGA×BSA and mPASI correlation was higher with increasing psoriasis severity.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gold LS, Hansen JB, Patel D, et al. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. J Am Acad Dermatol. 2020. PMID: 32430142. doi:10.1016/j.jaad.2020.02.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。